Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis

被引：26

作者：

Kelley, TW

Alkan, S

Srkalovic, G

Hsi, ED

机构：

[1] Cleveland Clin Fdn, Dept Clin Pathol, Cleveland, OH 44195 USA

[2] Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA

[3] Cleveland Clin Fdn, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA

[4] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA

来源：

LEUKEMIA RESEARCH | 2004年 / 28卷 / 08期

关键词：

bortezomib; chronic lymphocytic leukemia; proteasome inhibitor; NF-kappa B;

D O I：

10.1016/j.leukres.2003.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New options are needed for the treatment of B-cell chronic lymphocytic leukemia (CLL). Proteasome inhibitors represent a potential therapeutic strategy. One such agent, bortezomib, was recently approved for the treatment of refractory multiple myeloma. In this study, lymphocytes were isolated from the blood of CLL patients, treated in vitro with bortezomib, and evaluated for apoptosis by flow cytometry. Bortezomib promoted apoptosis in CLL cells in a dose- and time-dependent manner. At 18 h incubation time, 10 nM bortezomib induced an average 4.27 fold (+/-2.57) increase in the percentage of apoptotic cells versus untreated controls. These data indicate that bortezomib has in vitro activity in CLL and support further investigations of this promising new drug. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：845 / 850

页数：6

共 13 条

[1]

Aghajanian C, 2002, CLIN CANCER RES, V8, P2505

[2] Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex [J].